Screener
Veradermics MANE Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfNotesPayable.
The source filing: Veradermics’s 10-K, filed March 30, 2026.
- Filed
- Mar 30, 2026, 5:35 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001827635-26-000013
| (in thousands) | Year Ended December 31, 2025 | 2024 |
|---|---|---|
| Issuance of convertible notes | — | 8,507 |
| Issuance of Series B preferred stock | 8,433 | 53,097 |
| Issuance of Series C preferred stock | 151,000 | — |
| Payment of promissory note | — | (845) |
| Preferred stock issuance costs | (447) | (283) |
| Exercise of stock options | 156 | — |
| Net cash provided by financing activities | 159,142 | 60,476 |
| Net increase (decrease) in cash and cash equivalents | (31,318) | 36,788 |
Item 16. Form 10-K Summary
FAQ
- What is Veradermics's debt repayments?
- Veradermics (MANE) reported debt repayments of $0 in Q4 2025.
- How has Veradermics's debt repayments changed year-over-year?
- Veradermics's debt repayments decreased by 100.0% year-over-year, from $211.25K to $0.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Veradermics's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude